miglustat has been researched along with Epilepsies, Myoclonic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cardarelli, RA; Chen, Y; Gaval-Cruz, M; Higurashi, N; Hirose, S; Horiuchi, Y; Ishizuka, K; Kai, M; Kano, S; Kato, TA; Koga, M; Kondo, MA; Lee, Y; Maegawa, G; O'Donnell, P; Obie, C; Okano, H; Rapoport, JL; Sawa, A; Sedlak, TW; Seshadri, S; Srivastava, R; Tristan, C; Valle, D; Wilson, AM; Yuan, M | 1 |
| Alfonso, P; Capablo, JL; de Cabezón, AS; Franco, R; Giraldo, P; Pocovi, M | 1 |
2 other study(ies) available for miglustat and Epilepsies, Myoclonic
| Article | Year |
|---|---|
Clinical utility of neuronal cells directly converted from fibroblasts of patients for neuropsychiatric disorders: studies of lysosomal storage diseases and channelopathy.
Topics: 1-Deoxynojirimycin; Action Potentials; Basic Helix-Loop-Helix Transcription Factors; Cell Differentiation; Epilepsies, Myoclonic; Fibroblasts; G(M2) Ganglioside; Gene Expression; Genetic Vectors; Glycoside Hydrolase Inhibitors; Humans; Lentivirus; Nerve Tissue Proteins; Neurons; Plasmids; Primary Cell Culture; Tay-Sachs Disease; Transcription Factors; Transduction, Genetic; Transgenes | 2015 |
Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination.
Topics: 1-Deoxynojirimycin; Adult; Comorbidity; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Dystonia; Electroencephalography; Enzyme Inhibitors; Epilepsies, Myoclonic; Gaucher Disease; Glucosylceramidase; Humans; Male; Nervous System Diseases; Recombinant Proteins; Syndrome; Treatment Outcome | 2007 |